Sp191

PRACTICAL RECOMMENDATIONS ON ADVERSE EVENT DISCLOSURE. LESSONS FROM THE TRENCHES

Date
May 6, 2023
Explore related products in the following collection:

Society: AGA

As a procedural specialty, adverse events and complications will touch every provider in the course of their career. This session will provide attendees an overview of this aspect of our professional responsibility and response to adverse events. The session will start with an overview of how to create a culture of reporting and quality assurance. Following this overview, thought leaders in the area will discuss practical tips on how to respond to patients and colleagues after an adverse event. The session will close with an innovative approach to teaching and practicing these skills. Clinicians, program directors and practice and QI leaders will benefit from attending this session and leave with new insights and practical approaches on this topic.

Presenter

Speaker Image for Vivek Kaul
University of Rochester Medical Center

Tracks

Related Products

Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for PANEL DISCUSSION
PANEL DISCUSSION
As a procedural specialty, adverse events and complications will touch every provider in the course of their career. This session will provide attendees an overview of this aspect of our professional responsibility and response to adverse events…
Thumbnail for A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…